- Home
- ATER vs SNGX Comparison
ATER vs SNGX Comparison
Compare ATER & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATER
- SNGX
- Stock Information
- Founded
- ATER 2014
- SNGX 1987
- Country
- ATER United States
- SNGX United States
- Employees
- ATER N/A
- SNGX N/A
- Industry
- ATER Home Furnishings
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ATER Consumer Discretionary
- SNGX Health Care
- Exchange
- ATER Nasdaq
- SNGX Nasdaq
- Market Cap
- ATER 10.4M
- SNGX 10.1M
- IPO Year
- ATER N/A
- SNGX 1987
- Fundamental
- Price
- ATER $0.98
- SNGX $2.86
- Analyst Decision
- ATER
- SNGX Strong Buy
- Analyst Count
- ATER 0
- SNGX 1
- Target Price
- ATER N/A
- SNGX $6.00
- AVG Volume (30 Days)
- ATER 121.7K
- SNGX 10.2M
- Earning Date
- ATER 08-13-2025
- SNGX 08-14-2025
- Dividend Yield
- ATER N/A
- SNGX N/A
- EPS Growth
- ATER N/A
- SNGX N/A
- EPS
- ATER N/A
- SNGX N/A
- Revenue
- ATER $85,668,000.00
- SNGX N/A
- Revenue This Year
- ATER N/A
- SNGX N/A
- Revenue Next Year
- ATER $7.48
- SNGX N/A
- P/E Ratio
- ATER N/A
- SNGX N/A
- Revenue Growth
- ATER N/A
- SNGX N/A
- 52 Week Low
- ATER $0.90
- SNGX $1.09
- 52 Week High
- ATER $3.84
- SNGX $6.23
- Technical
- Relative Strength Index (RSI)
- ATER 36.18
- SNGX 49.77
- Support Level
- ATER $0.94
- SNGX $2.72
- Resistance Level
- ATER $1.07
- SNGX $3.11
- Average True Range (ATR)
- ATER 0.05
- SNGX 0.49
- MACD
- ATER 0.01
- SNGX -0.10
- Stochastic Oscillator
- ATER 33.41
- SNGX 3.99
About ATER Aterian Inc.
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operates brands, including HomeLabs, Squatty Potty, Healing Solutions, PurSteam, and others. The company generates revenue through the online sales of various consumer products that are sold online.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).